Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
US80105B1017
Mon, 15.05.2023       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech:   - Significant increase in sales in the first half of the year - Further reduction of the operating loss   Hamburg, February 13, 2023: In the first six months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,656. In the same period of the previous year the co [ … ]
Technical analysis
To the publication
Mon, 15.05.2023       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech:   - Significant increase in sales in the first half of the year - Further reduction of the operating loss   Hamburg, February 13, 2023: In the first six months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,656. In the same period of the previous year the co [ … ]
Technical analysis
To the publication
Mon, 13.02.2023       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech:   - Significant increase in sales in the first half of the year -  Further reduction of the operating loss   Hamburg, February 13, 2023: In the first six months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,656. In the same period of the previous year the c [ … ]
Technical analysis
To the publication
Mon, 13.02.2023       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech:   - Significant increase in sales in the first half of the year -  Further reduction of the operating loss   Hamburg, February 13, 2023: In the first six months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,656. In the same period of the previous year the c [ … ]
Technical analysis
To the publication
Fri, 11.11.2022       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech: - Sales of USD 41,029 in first quarter -  For the first time, positive quarterly result in the company's history   Hamburg, November 11, 2022: In the first three months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 41,029. In the same period of the previous ye [ … ]
Technical analysis
To the publication
Fri, 11.11.2022       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech: - Sales of USD 41,029 in first quarter -  For the first time, positive quarterly result in the company's history   Hamburg, November 11, 2022: In the first three months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 41,029. In the same period of the previous ye [ … ]
Technical analysis
To the publication
Wed, 12.10.2022       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech: Increase in sales in the first quarter of 121% Highest quarterly sales in the company's history   Hamburg, October 12, 2022: According to preliminary and unaudited numbers, the Sangui Biotech International Inc. was able to increase its license revenue from the wound spray Granulox in the first quarter of its fiscal year 2023 (01. [ … ]
Technical analysis
To the publication
Wed, 12.10.2022       Sangui BioTech International Inc.
US80105B1017

Sangui BioTech: Increase in sales in the first quarter of 121% Highest quarterly sales in the company's history   Hamburg, October 12, 2022: According to preliminary and unaudited numbers, the Sangui Biotech International Inc. was able to increase its license revenue from the wound spray Granulox in the first quarter of its fiscal year 2023 (01. [ … ]
Technical analysis
To the publication
Thu, 29.09.2022       Sangui BioTech International Inc.
US80105B1017

  Sangui BioTech:   - Sales of USD 69,190 in fiscal year 2022 - Reduction of the operating loss   Hamburg, September, 29 2022: In the fiscal year 2022 (01/07/2021 to 30/06/2022) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 69,190. In the same period of the previous year the comparable reven [ … ]
Technical analysis
To the publication
Thu, 29.09.2022       Sangui BioTech International Inc.
US80105B1017

  Sangui BioTech:   - Sales of USD 69,190 in fiscal year 2022 - Reduction of the operating loss   Hamburg, September, 29 2022: In the fiscal year 2022 (01/07/2021 to 30/06/2022) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 69,190. In the same period of the previous year the comparable reven [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 07.10.2024, Calendar Week 41, 281st day of the year, 85 days remaining until EoY.